Maxcyte (MXCT) Capital Expenditures (2020 - 2026)

Maxcyte (MXCT) has reported Capital Expenditures for 7 consecutive years, with -$1.6 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Capital Expenditures fell 369.86% year-over-year to -$1.6 million in Q2 2026; TTM through Jun 2026 was -$918000.0, a 151.28% decrease from a year earlier, with the FY2025 full-year figure at $1.8 million, up 7.09% from the prior year.
• Capital Expenditures was -$1.6 million for Q2 2026 at Maxcyte, down from $127000.0 in the prior quarter.
• Over five years, Capital Expenditures peaked at $6.8 million in Q2 2022 and troughed at -$1.6 million in Q2 2026.
• A 5-year average of $1.3 million and a median of $618500.0 in 2025 frame the typical range for Capital Expenditures.
• Across the five-year window, Capital Expenditures surged 1844.73% in 2022 and tumbled 369.86% in 2026, its largest moves.
• Over 5 years, Capital Expenditures stood at $2.2 million in 2022, then plunged by 58.3% to $915000.0 in 2023, then plunged by 83.93% to $147000.0 in 2024, then surged by 57.14% to $231000.0 in 2025, then slumped by 782.25% to -$1.6 million in 2026.
• The last three Capital Expenditures figures came in at -$1.6 million (Q2 2026), $127000.0 (Q1 2026), and $231000.0 (Q4 2025), per Business Quant data.